SCHEMBL4011282

SCHEMBL4011282

O=C(O)N[C@H]1CCCN(c2ccccc2)C1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.54
NOTUM Q6P988 1/20 0.51
MAPK1 P28482 2/20 0.49
USP2 O75604 1/20 0.49
PPARA Q07869 8/20 0.48
PPARD Q03181 5/20 0.48
USP30 Q70CQ3 2/20 0.48
CASR P41180 1/20 0.46
SCD5 Q86SK9 1/20 0.46
ALDH1A1 P00352 1/20 0.46
PPARG P37231 2/20 0.44
NAMPT P43490 1/20 0.44
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4011287 1.00 CNR1 (0.64) CNR1SMN1; SMN2NOTUMMAPK1USP2
SCHEMBL14859926 1.00 CNR1 (0.64) CNR1SMN1; SMN2NOTUMMAPK1USP2
SCHEMBL15212339 0.90 NOTUM (0.58) CNR1SMN1; SMN2NOTUMUSP30CASR
SCHEMBL17846589 0.88 CNR1 (0.62) CNR1SMN1; SMN2NOTUMMAPK1USP2
SCHEMBL16422448 0.87 NOTUM (0.55) CNR1SMN1; SMN2NOTUMMAPK1PPARA
SCHEMBL6365484 0.87 CNR1 (0.51) CNR1SMN1; SMN2MAPK1USP2PPARA
SCHEMBL16570341 0.87 CNR1 (0.51) CNR1SMN1; SMN2USP2PPARAPPARD
SCHEMBL21526469 0.87 CNR1 (0.51) CNR1SMN1; SMN2USP2PPARAPPARD
SCHEMBL21526427 0.87 CNR1 (0.51) CNR1SMN1; SMN2USP2PPARAPPARD
SCHEMBL16422346 0.87 NOTUM (0.55) CNR1SMN1; SMN2NOTUMMAPK1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 CNR1 516/4885SMN1; SMN2 3627/4885NOTUM 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.